Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?-Reference-Cited by-同舟云学术

Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?

Published:2022-06-11 Issue:9 Volume:15 Page:2096-2104
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Zheng Songmao¹,Prell Rodney²,Sheng Jennifer³,Wang Yow‐Ming⁴,Hamuro Lora³

Affiliation:

1. Clinical and Quantitative Pharmacology Adagene San Diego California USA

2. Safety Assessment, Genentech South San Francisco California USA

3. Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb Princeton New Jersey USA

4. Office of Clinical Pharmacology, OTS/CDER/FDA Silver Spring Maryland USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13345

Reference24 articles.

1. Catumaxomab

2. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

3. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

4. 2012 11/20. United States Prescribing Information (USPI) PERJETA®(pertuzumab).https://www.gene.com/download/pdf/perjeta_prescribing.pdf. Accessed November 20 2021.

5. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology;Clinical Pharmacology & Therapeutics;2024-06-02

2. Analysis of the use of excipients in medicines of biological origin;Reports of Vinnytsia National Medical University;2024-03-14

3. PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy;Frontiers in Immunology;2022-11-28